Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

• Status: No longer available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a single-center, open label, non randomized, compassionate use protocol in patients with advanced solid tumor malignancies who were previously enrolled in the phase I study (NCT00878189) of this agent.

Details

• Lead Sponsor: University of Colorado, Denver
• Collaborators: Pfizer; SpringWorks Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Patients who are currently enrolled in A8641014 for > 1 year are eligible

Exclusion Criteria:

• Prior treatment with a gamma secretase inhibitor for treatment of cancer

• Patients taking Tamoxifen

• Patients with active graft versus host disease

• Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness

• Patients who are pregnant or breast-feeding

• Patients with clinical evidence of central nervous system disease